Drug intelligence / Profile preview

BIA 34

Development stage: Preclinical
Lead developer: Bial

Overview

BIA 34 is an investigational drug candidate currently in the preclinical stage of development by the pharmaceutical company Bial (BIAL-Portela & Cia SA). It is being explored for potential applications in treating nervous system diseases. Due to its early stage of development, specific information regarding its chemical modality, biological target, and precise mechanism of action has not yet been released by the developer. It is part of a series of preclinical assets in Bial's pipeline aimed at addressing neurological and psychiatric conditions.

Beyond the preview

Go deeper on BIA 34.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BIA 34.

Explore the full profile